Endocrinology
From the Journals
How Lp(a) can help improve ASCVD risk assessment
Calcium scores and lipoprotein(a) levels predict 10-year risk independent of each other, and together could swing shared decision-making about...
From the Journals
Full-press therapy rare in diabetes with ASCVD
From the Journals
Statin intolerance ‘overestimated and overdiagnosed’
Fewer than 10% of patients experience statin intolerance, meaning that the vast majority of patients can be treated effectively, with very good...
From the Journals
Vitamin D shows no survival benefit in nondeficient elderly
“This is not dissimilar to research with many other nutrients showing that increasing intake above the adequate intake has no further health...
Feature
Uptake uncertain for potent new LDL-lowerer inclisiran
Inclisiran, a novel small interfering RNA drug that inhibits PCSK9, made its U.S. debut in early 2022 with cautious uptake prospects.
News
AHA advice for diabetes patients to stay heart healthy
Fewer than one in five Americans meet targets for blood sugar, blood pressure, and lipids.
News
COVID-19 linked to increased diabetes risk in youth
Two large databases indicate significantly increased diabetes risk among those with COVID-19 but not other acute respiratory illnesses.
News
ADA standards of care 2022: Screen more, personalize, use technology
The ADA’s new standards of care call for screening younger people and pregnant women earlier, along with furthering the trends toward...
Conference Coverage
SGLT2 inhibitor use tied to fewer atrial arrhythmias
From the Journals
Does vitamin D benefit only those who are deficient?
The results will “allow clinicians to better weigh the potential benefits of supplementation against its risk,” such as financial cost.
Conference Coverage
Empagliflozin a winner in challenging arena of stabilized acute HF
Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of...